Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a note issued to investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 price target on shares of Trevena in a report on Thursday, November 14th.

Trevena Stock Performance

TRVN stock opened at $1.48 on Tuesday. The stock has a market cap of $1.28 million, a P/E ratio of -0.03 and a beta of 1.05. The firm has a 50 day simple moving average of $1.70 and a 200 day simple moving average of $2.34. Trevena has a 52 week low of $1.13 and a 52 week high of $14.37.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.